Literature DB >> 8581559

An endogenous dopaminergic neurotoxin: implication for Parkinson's disease.

M B Mattammal1, J H Haring, H D Chung, G Raghu, R Strong.   

Abstract

Oxidation of dopamine by monoamine oxidase results in the endogenous metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). The toxicity of DOPAL for dopaminergic neurons was investigated using rat neostriatal synaptosomes, PC-12 cells and cultures of fetal rat dissociated mesencephalon. The Na(+)-dependent uptake of [3H]DOPAL in synaptosomes was inhibited by mazindol. DOPAL selectively inhibited dopamine uptake but not [14C]GABA uptake, induced membrane damage and liberation of dopamine into the medium. Incubation of PC-12 cells with 6.5 microM of DOPAL for 24 h caused degeneration of the neuritic process, and the number of viable cells were reduced by 25% of control. There were practically no surviving cells after 24 h of incubation with 33 microM of DOPAL. After 8 h of treatment with 33 microM of DOPAL, dopamine and 3,4-dihydroxyphenylacetic acid content in the cells were reduced by 38% and 53% of control. DOPAL-induced cell damage released lactic acid dehydrogenase into the incubation media. This toxic effect of DOPAL was time- and concentration-dependent. In mesencephalic cultures, after exposure to 33 microM of DOPAL, the surviving TH+ cells showed rounded cell body, and fibre network was highly reduced. These results indicate DOPAL is a neurotoxin and may be involved in the degeneration of dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8581559     DOI: 10.1016/1055-8330(95)90016-0

Source DB:  PubMed          Journal:  Neurodegeneration        ISSN: 1055-8330


  37 in total

1.  Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.

Authors:  Lydia M Mexas; Virginia R Florang; Jonathan A Doorn
Journal:  Neurotoxicology       Date:  2011-04-14       Impact factor: 4.294

2.  Catechols in post-mortem brain of patients with Parkinson disease.

Authors:  D S Goldstein; P Sullivan; C Holmes; I J Kopin; M J Basile; D C Mash
Journal:  Eur J Neurol       Date:  2010-11-12       Impact factor: 6.089

3.  3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine.

Authors:  Yunden Jinsmaa; Yehonatan Sharabi; Patti Sullivan; Risa Isonaka; David S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2018-04-26       Impact factor: 4.030

4.  Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde.

Authors:  Courtney Holmes; Noel Whittaker; Jorge Heredia-Moya; David S Goldstein
Journal:  Clin Chem       Date:  2010-03-05       Impact factor: 8.327

Review 5.  How does homeostasis happen? Integrative physiological, systems biological, and evolutionary perspectives.

Authors:  David S Goldstein
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-01-16       Impact factor: 3.619

6.  Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.

Authors:  Lydia M M Vermeer; Virginia R Florang; Jonathan A Doorn
Journal:  Brain Res       Date:  2012-07-31       Impact factor: 3.252

7.  A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease.

Authors:  David S Goldstein; Patricia Sullivan; Courtney Holmes; Gary W Miller; Yehonatan Sharabi; Irwin J Kopin
Journal:  J Neurochem       Date:  2014-06-13       Impact factor: 5.372

8.  Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.

Authors:  Jonathan W Werner-Allen; Sarah Monti; Jenna F DuMond; Rodney L Levine; Ad Bax
Journal:  Biochemistry       Date:  2018-02-15       Impact factor: 3.162

Review 9.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

10.  L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.

Authors:  Anthony Donsante; Patricia Sullivan; David S Goldstein; Lauren R Brinster; Stephen G Kaler
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.